Peritubular myoid cells have a role in postnatal testicular growth by Nurmio, Mirja et al.
© 2012 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Spermatogenesis  79
Spermatogenesis 2:2, 79-87; April/May/June 2012; © 2012 Landes Bioscience
report  report
*Correspondence to: Mirja Nurmio; Email: mihanu@utu.fi
Submitted: 02/09/12; Revised: 03/19/12; Accepted: 03/19/12
http://dx.doi.org/10.4161/spmg.20067
Introduction
Postnatal increase in the number of Sertoli cells is believed to 
determine final testicular size and later total sperm output. Follicle-
stimulating hormone (FSH) is known to stimulate the proliferation 
of Sertoli cells and to induce testicular growth. Indeed, mice lacking 
FSH receptor show decreased testicular growth1 and also humans 
who have non-functional FSH receptor have small testicular size.2 
In agreement with these findings Sertoli cell proliferation3-6 and 
testicular growth7,8 can be stimulated by FSH administration dur-
ing postnatal period. Similarly, postnatal hemicastration (HCA), 
which is known to increase pituitary FSH secretion by reducing 
inhibin B production, stimulates testicular hypertrophy of the con-
tralateral testis.9-11 Adequate postnatal testicular growth is impor-
tant for future fertility since the final number of Sertoli cells in the 
adult testis correlates with total sperm output.12,13
Less is known about the role of peritubular myoid cells 
in testicular growth. Proliferation of the peritubular myoid 
cells14 coincides with the expansion of the Sertoli cells during 
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postnatal period which ceases at the postnatal day 15 in the 
rat.15,16 Supporting their close interaction during development, 
communication between the peritubular myoid and the Sertoli 
cells is required for the formation of basal lamina during post-
natal development.17,18 Thus, peritubular myoid cell proliferation 
may play a more important role in the regulation of testicular 
growth than earlier appreciated.
In order to investigate the role of the peritubular myoid cells 
in testicular growth in rats, we used two traditional models to 
induce testicular growth: FSH treatment and hemicastration. 
Since we have earlier shown that the inhibition of peritubular 
myoid cell proliferation during postnatal period is able to decrease 
final testicular size19 we combined FSH administration or hemi-
castration with imatinib mesylate treatment (Glivec®, STI571, 
Novartis Pharma). FSH treatment and hemicastration increased 
the length of the seminiferous cords and testicular weight by 
increasing the early proliferation of peritubular myoid cells and 
later also the proliferation of the Sertoli cells. Imatinib blocked 
the FSH and hemicastration-induced testicular hypertrophy and © 2012 Landes Bioscience.
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was also able to decrease the proliferation of the human testicular 
peritubular cells (HTPCs) in vitro.
Results
FSH administration and hemicastration induced testicular 
growth. Hemicastration and FSH treatment increased plasma 
FSH levels, resulting in testicular growth at the postnatal age of 
8 d (Table 3). FSH treatment caused 45% and hemicastration 
9% increase in testicular weight when compared with the control 
value, but the body weights did not change. Faster longitudinal 
outgrowth of seminiferous cords and increased proliferation rate 
of Sertoli cells and peritubular myoid cells (Figs. 1 and 2) were 
evident in both the hemicastrated group and FSH-treated group. 
Proliferation of the peritubular myoid cells increased earlier (day 
5) than that of the Sertoli cells (day 8), suggesting a role in the 
FSH-induced testicular growth (Table 3 and Fig. 1). No signifi-
cant changes in germ or Sertoli cell numbers per area, in the pro-
liferation rate of germ cells or in the diameter of seminiferous 
cords were detected after FSH administration or hemicastration 
when compared with controls at the postnatal age of 8 d indi-
cating that the testicular growth was due to lengthening of the 
testicular seminiferous cords/tubules.
To further study the mechanism behind FSH- and hemicas-
tration-induced testicular hypertrophy, we analyzed transcript 
levels of SCF, c-kit, GDNF, Ret, PDGF ligands and receptors. 
Significant ontogenetic changes in the levels of these transcripts 
were found. Transcript levels of SCF, c-kit, PDGFB and Ret were 
significantly increased and PDGFA significantly decreased from 
postnatal age of 5 d to postnatal age of 8 d (Fig. 3) at these age 
points. FSH administration and hemicastration did not signifi-
cantly affect the expression pattern of SCF, c-kit, Ret or PDGF 
ligands (Fig. 3). Only PDGFR-α expression was significantly 
increased after hemicastration on postnatal day 8 (Fig. 3) and 
GDNF expression significantly decreased after FSH-treatment 
and hemicastration on postnatal day 5 (Fig. 3).
Imatinib decreased postnatal testicular growth. Imatinib 
treatment alone significantly decreased plasma levels of FSH, tes-
ticular size, length of the seminiferous cords and proliferation of 
the peritubular myoid cells on postnatal day 8 (Table 3 and Fig. 1). 
Instead, imatinib increased the number of the proliferating 
Sertoli cells significantly and led to a significantly increased num-
ber of Sertoli cells per area (Table 3 and Figs. 1 and 2). Imatinib 
treatment did not affect the total number or the number of pro-
liferating germ cells on postnatal day 8.
Imatinib abolished testicular growth induced by FSH treat-
ment and hemicastration. Imatinib treatment was able to abolish 
both the FSH- and hemicastration-induced longitudinal growth 
of seminiferous cords and significantly decreased peritubular 
myoid cell proliferation in both of these treatment groups (Fig. 1). 
Proliferation of the Sertoli cells was significantly decreased in 
FSH-treated group but the decrease in the hemicastrated group 
was more modest and did not reach statistical significance. 
Imatinib treatment in combination with FSH administration or 
hemicastration had not significant effect on the total number of 
Sertoli cells per area (Table 3). The diameter of the seminiferous 
Figure 1. the effects of FSH administration (FSH), hemicastration (HCA) 
and imatinib treatment (I) on the seminiferous cord length and the 
number of BrdU-positive Sertoli and peritubular myoid cells. results 
are means + SeM * and a–c indicate significant differences (p < 0.05) 
between the experimental groups.© 2012 Landes Bioscience.
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FSH treatments may affect the PDGF signal cascade. Our find-
ing is not in agreement with the previous study by Gnessi and 
coworkers where they showed that FSH dose dependently inhib-
its PDGF production.34 Possible explanation is that our work was 
done in vivo, and Gnessi and coworkers investigated the effects of 
FSH on PDGF production in in vitro cultures.
To further study the mechanism behind FSH- and hemicas-
tration-induced testicular hypertrophy, we analyzed also tran-
script levels of SCF, c-kit, GDNF and Ret. However, pathways 
analyzed here seemed not to be similarly affected. An obvious 
limitation of the present study is that the measurements of the 
steady-state mRNA levels were done in the whole testes and 
therefore may not properly reflect changes at the cellular level.
Since we had earlier shown that tyrosine kinase inhibitor 
imatinib caused inhibition of peritubular myoid cell prolifera-
tion during the postnatal period and decreased final testicular 
size,19 we used imatinib to test, whether it could interfere in the 
communication of Sertoli cells and peritubular myoid cells, par-
ticularly PDGF signaling. Sertoli cells produce PDGFs that act 
on myoid cells harboring PDGF receptors.34,35 Imatinib is a small 
molecular analog of ATP that inhibits the Bcr-Abl, PDGFRα, 
PDGFRβ, c-Fms, Arg and c-kit tyrosine kinases.36-39 PDGFs 
stimulate gonocyte and peritubular myoid cell proliferation.40-42 
C-kit receptor, in turn is known to be expressed on differenti-
ating spermatogonia and Leydig cells,43-45 and its ligand SCF 
is produced by Sertoli cells.44,46 Treatment with imatinib alone 
led to a significant decrease in the proliferation of the peritubu-
lar myoid cells, without decreasing the number of proliferating 
Sertoli cells, which are known to be c-kit and PDGF receptor-
negative. Present data confirms our earlier observations showing 
that a short 3-d postnatal imatinib treatment and inhibition of 
peritubular myoid cell proliferation is able to affect the final tes-
ticular size in adult rats.19
The present study demonstrates that imatinib treatment is 
able to block the FSH-stimulated testicular growth and hemicas-
tration-induced compensatory hypertrophy of the contralateral 
testis. When imatinib was combined with FSH administration 
or hemicastration, especially the early proliferation of peritubular 
myoid cells, which were shown to initiate the testicular hyper-
trophy, decreased significantly. This blocked the FSH-induced 
cords increased after combined administration of FSH and ima-
tinib (Table 3). Imatinib treatment in combination with FSH 
administration or hemicastration did not significantly affect the 
number of germ cells.
Imatinib inhibited the proliferation of the human testicular 
peritubular cells (HTPCs) in vitro. Effects of increasing con-
centrations of imatinib on viability of human testicular peritu-
bular cells are shown in Figure 4A. Viability of the cells was not 
affected by the concentrations ≤ 10 μM but was dose depend-
ently reduced with higher concentrations. Imatinib concentra-
tion of 10 μM was therefore used for further analysis. Exposure 
of human peritubular cells to 10 μM imatinib had no effect on 
their proliferation or number per ml when compared with control 
values. However, when HTPCs were stimulated with 5 ng/ml of 
recombinant human PDGF, the natural ligand of the PDGFα 
and  β receptors,31 a significant increase in cell proliferation 
(Fig. 4D) and cell number/ml (Fig. 4C) was detected. Treatment 
with 10 μM imatinib effectively blocked this PDGF-induced 
proliferation and increase in HTPC numbers (Fig. 4B and C).
Discussion
The aim of the present study was to investigate the role of peri-
tubular myoid cells in postnatal testicular growth. Therefore two 
traditional models to stimulate Sertoli cell proliferation, FSH 
administration and hemicastration, were compared and com-
bined with imatinib treatment. Our present data indicate that 
peritubular myoid cells play a more critical role in determination 
of final testicular size than earlier thought.
Interestingly, both FSH administration and hemicastration 
increased first peritubular myoid cell proliferation, already on 
the postnatal day 5. Three days later an increase in the number 
proliferating Sertoli cells was seen and accordingly the length of 
the seminiferous cords and testis weight increased. Since Sertoli 
cells are the only cells expressing FSH receptors in the testis,32,33 
FSH administration and hemicastration most probably affected 
the proliferation of peritubular myoid cells through paracrine 
factors like PDGF ligands. Increased expression level of PDGF 
receptor α was detected after hemicastration, and there was a 
tendency to higher PDGFβ, suggesting that hemicastration and 
Figure 2. the immunohistochemical detection of BrdU incorporation (green fluorescence) and Wt-1 positive Sertoli cells (red fluorescence) in the 
testis of control (CtrL), imatinib-treated (I) FSH-treated (FSH) and hemicastrated (HCA) rats at the age of 8 d. proliferating peritubular myoid cells are 
identified according to BrdU staining and peritubular location (→) and proliferating Sertoli cells by double staining with BrdU and Wt-1 (▶).© 2012 Landes Bioscience.
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Figure 3. the effects of FSH administration and hemicastration on the relative levels of testicular SCF, c-kit, GDNF, ret, pDGF-A, pDGF-B, pDGFrα and 
pDGFrβ gene expression in 5- and 8-d-old rats. results are means + SeM *depicts the statistically significant difference.© 2012 Landes Bioscience.
Do not distribute.
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Turku University. Aspen chips (Tapvei Co.) were used as bedding 
material and animals were maintained on a 12 h light/12 h dark 
cycle (lighted from 07 to 19 h). Animals had free access to tap 
water and standard laboratory animal feed [Commercial RM3 
(E) SQC, Special Diet Service].
The day of birth was designed as day 0. Two days after birth, 
the size of each litter was reduced by random selection to 8. 
Litters were divided into nine treatment groups (Table 1) and 
every group included pups from two or more litters.
In order to induce the growth of the contralateral testis, 
one group of animals were unilaterally castrated, i.e., hemi-
castrated (HCA) a day after birth (day 1) using cooling as 
analgesia.20 Another group of male pups was exposed with lyoph-
ilized recombinant human FSH (Puregon) dissolved in water 
(200 IU/kg, s.c.) daily from day 1 onwards to stimulate tes-
ticular hypertrophy. Part of the hemicastrated and FSH-
exposed pups and one group of intact pups were treated with 
imatinib mesylate (150 mg/kg; Glivec®, STI571, Novartis 
Pharmaceuticals Corporation) dissolved in water and injected 
(150 μl) intracavitally into the stomach once daily on postna-
tal days 5–7 as described in reference 19. Control animals were 
injected in the same manner with water alone. The experimen-
tal groups and the timeline of the experiment are presented in 
Table 1. In 30% of experimental animals combined adminis-
tration of FSH and imatinib caused lethal reaction up to 24 h 
after treatment. Animals became lethargic and did not survive 
the planned experiment. The reason for mortality remained 
accelerated tubular outgrowth and prevented the hypertrophy of 
the testis. Observation suggests that peritubular myoid cell pro-
liferation is a significant determinant of longitudinal growth of 
the seminiferous cords and the final testicular size.
The inhibition of myoid cell proliferation was seen also in 
human peritubular cells. Imatinib affected the cells that were 
actively induced to proliferate by PDGF stimulation. The obser-
vation confirms that imatinib exerts its function in peritubular 
cells by interfering with active protein tyrosine kinase cascade. 
Thus, activity of imatinib in a particular cell should be selective 
in terms of how active this cascade is in the cell. During postna-
tal testicular development such ligand stimulation and cascade 
activation is known to occur in peritubular myoid precursor and 
germ cells.
In conclusion, the present study provides new evidence that 
peritubular myoid cells have an important role in the longitudi-
nal growth of seminiferous cords in the postnatal rat testis. Thus, 
Sertoli cell proliferation is not the only determinant of postnatal 
testicular growth but peritubular myoid cells participate in this 
regulation and affect the growth of basement membrane lined by 
Sertoli cells.
Materials and Methods
Animals and treatments. Sprague-Dawley rats were housed in 
plastic cages (Tecniplast) in a climate-controlled room at 21 ± 
3°C with a relative humidity of 55 ± 15% at the Animal Center of 
Figure 4. the effect of imatinib in cultured human testicular peritubular cells (HtpCs) on (A) cell viability (Atp assay), (B) the proportion of proliferating 
cells showing a mitotic figure (%) and (C) total cell counts. Imatinib blocked the pDGF-induced increase in cell proliferation of HtpCs. (D) example of a 
mitotic figure stained with DApI indicating a proliferating HtpC. Bar: 3 μm. results are means + SeM. Different letters indicate significant differences. 
Numbers in columns indicate the number of patients used for cell harvesting. rLU, relative luminescence units.© 2012 Landes Bioscience.
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polyclonal antibody against WT-1 (180) (Santa Cruz; 1:100 dilu-
tion) was used for identifying Sertoli cells and an anti-BrdU anti-
body (a mouse monoclonal antibody, Roche Diagnostics Corp., 
6 μl/100 μl TBS) was utilized to label proliferating cells. Cell 
nuclei were stained with DAPI (0.5 ng/ml, Sigma). After second-
ary antibody incubation the slides were examined under fluores-
cence microscope.
All Sertoli and germ cells as well as BrdU-positive peritubular 
myoid, Sertoli and germ were counted from the minimum area of 
300,000 μm2 per testis section (n = 4 per group).
Hormone assays. Plasma levels of FSH were measured employ-
ing immunofluorometric assay as described in reference 24. For 
the FSH assay, the sensitivity was 0.1 μg/L and the intra- and 
interassay coefficients of variation 4.4% and 10.4%, respectively, 
at a level of 4.8 μg/L.
The FSH levels of eight animals in each experimental group 
were measured.
Extraction of RNA and performance of quantitative 
RT-PCR. Total RNA was extracted from testicular tissue using 
the TRIzol reagent (Invitrogen) according to the manufacturer’s 
instructions and treated with the DNase I Amplification Grade 
Kit (Invitrogen) as described in reference 25. Briefly, quantitative 
RT-PCR was performed employing the DyNAmo SYBR Green 
2-Step qRT-PCR Kit (Finnzymes), with the inclusion of controls 
without reverse transcriptase. For each set of conditions four 
independent samples were analyzed in triplicate. The mRNA lev-
els of platelet derived growth factors Pdgfa and Pdgfb and their 
receptors Pdgfra and Pdgfrb, c-kit, Stem cell factor (Scf), Glial 
cell line-derived neurotropic factor (Gdnf) and its receptor Ret 
were analyzed relative to the levels of glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh), hypoxanthine guanine phosphoribosyl 
transferase 1 (Hprt1) and ribosomal protein S26 (S26) mRNAs. 
The primers and annealing temperatures used in this regard are 
presented in Table 2.
Culture of human peritubular cells. Isolation of human 
testicular peritubular cells (HTPC) was performed as previ-
ously described in references 26–28. HTPCs originate from 
unsolved. Substitute animals were injected to maintain the 
group size large enough.
The animals were sacrificed by decapitation at the age of 5 or 8 
d. The weight of the body and testis were recorded and blood and 
testicular samples were collected. All animal experiments were 
approved by the Turku University Committee on the Ethics of 
Animal Experimentation.
Analysis of the diameter and length of seminiferous cords. 
In order to calculate the diameter and the length of the seminifer-
ous cords, Bouin-fixed 4-μm thick testicular sections (n = 4 per 
group) were stained with hematoxylin and eosin. Morphometric 
analysis involved the measurement of cord diameter and the 
proportion of testicular tissue made by interstitial tissue. Cord 
length was calculated by using a formula:21 length of the cord (m) 
= {weight of the testis (mg) x cord area (%)}/{π x [diameter of the 
cord (μm)/2)]2}. All analyses were performed utilizing a morpho-
metric program (Leica IM500 Version: 4.0; Leica Microsystems 
Imaging Solutions Ltd.).
The immunohistochemical detection of BrdU incorpora-
tion and the double staining with WT-1. BrdU (Roche Applied 
Science) (50 mg/kg) was injected intra peritoneally three hours 
prior to sacrificing the animal. The samples of testicular tis-
sue were fixed overnight with 4% paraformaldehyde-fixative, 
embedded in paraffin and cut to 4-μm thick sections. To detect 
BrdU-positive peritubular myoid cells, immunohistochemistry 
was performed for the testis samples following manufacturer’s 
instructions (Roche Diagnostics Corp.), as described in refer-
ence 19. Shortly, monoclonal anti-BrdU (6 μl/100  μl PBS, 
Roche Diagnostics Corp.) was used as the primary antibody 
and the secondary antibody treatment and visualization were 
performed utilizing the PowerVision immunohistochemistry kit 
(PowerVision + TM Poly-HRP IHC Kit Biotin-free, anti-mouse/
rabbit, ImmunoVision Technologies, Co.), according to the man-
ufacturer’s instructions.
Proliferating Sertoli and germ cells were detected using dou-
ble fluorescense immunohistochemistry with antibodies against 
BrdU and WT-1 as described in references 22 and 23. A rabbit 
Table 1. the experimental groups and the time-line for treatment of immature male rats
Age Group Treatment
1 d 2 d 3 d 4 d 5 d
5 d
CtrL Control
DeAtH FSH FSH x x x x
HCA Hemicastration x
1 d 2 d 3 d 4 d 5 d 6 d 7 d 8 d
8 d
CtrL Control
DeAtH
I Imatinib x x x
FSH FSH x x x x x x x
FSH + I
FSH x x x x x x x
Imatinib x x x
HCA Hemicastration x
HCA+I
Hemicastration x
Imatinib x x x© 2012 Landes Bioscience.
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Table 2. the primers used in qrt-pCr analysis
Primers for quantitative RT-PCR 
Gene Primer sequence Annealing temperature Product length GenBank accession number
Gapdh
5'-AGA CAG CCG CAt Ctt Ctt Gt-3' 
5'-Ctt GCC GtG GGt AGA GtC At-3'
55°C 207 bp NM_017008
Hbrt1
5'-AAG Ctt GCt GGt GAA AAG GA-3' 
5'-CCG CtG tCt ttt AGG Ctt tG-3'
54°C 185 bp NM_012583
S26
5'-AAG GAG AAA CAA CGG tCG tG-3' 
5'-GCA GGt CtG AAt CGt GGt G-3'
57°C 300 bp XM_001066146
c-kit
5'-GGC CtA GCC AGA GAC AtC AG-3' 
5'-CAt tCG GAA ACC ttC Ctt GA-3'
59°C 234 bp D12524
Scf
5'-CAA AAC tGG tGG CGA AtC tt-3' 
5'-GCC ACG AGG tCA tCC ACt At-3'
61°C 217 bp NM_021843
Pdgfra
5'-ACG ttC AAG ACC AGC GAG tt-3' 
5'-CAG ttt GAt GGA CGG GAG tt-3'
64°C 225 bp XM_214030
Pdgfrb
5'-ACC tGG tGG ACt ACC tGC AC-3' 
5'-tGt CCG CGt Att tGA tGt Gt-3'
63°C 234 bp NM_031525
Pdgfa
5'-GAG AtA CCC CGG GAG ttG At-3' 
5'-AAA tGA CCG tCC tGG tCt tG-3'
63°C 244 bp NM_012801
Pdgfb
5'-GtC GAG tCG GAA AGC tCA tC-3' 
5'-CAC tGC ACA ttG CGG ttA tt-3'
60.5°C 212 bp XM_001075973
Ret
5'-ACA GCC ttC CGt CtG AAA GA-3' 
5'-AAG CCC CGt ACA ACt tGA tG-3'
58°C 157 bp NM_012643
Gdnf
5'-GCC GAG ACA AtG tAC GAC AA-3' 
5'-CtG GAG CCA GGG tCA GAt AC-3'
57°C 206 bp NM_019139
Table 3. the effects of FSH administration and hemicastration (HCA) with or without imatinib treatment (I) on the serum levels of FSH and the morpho-
logical findings of postnatal testicular growth in rats
Parameter Age and treatment group
5d 8d
CTRL FSH HCA CTRL I FSH FSH + I HCA HCA+I
Body weight (n = 8) 13.7 ± 0.8 11.6a ± 0.2 13.5 ± 0.4 20.3c ± 0.8
12.8d ± 
0.2
21.0c ± 0.4 14.1d ± 0.6 20.8c ± 0.9 14.0d ± 0.9
FSH (ng/ml) (n = 8) 3.8 ± 0.4 26.1a ± 1.3 11.4 ± 1.4 5.3 ± 0.8 2.9d ± 0.5 15.6bc ± 0.7 50.0d ± 6.3 16.2bc ± 1.3 15.7 ± 1.6
testis weight (mg)  
(n = 8, except in HCA 
and HCA+I n = 16)
9.4 ± 0.04 7.8 ± 0.03 8.7 ± 0.04 17.5c ± 0.05
13.7d ± 
0.04
25.3bc ± 
0.08
21.0d ± 0.16 19.1ce ± 0.05 15.9d ± 0.06
Cord diameter (μm) 
(n = 4)
54.2 ± 0.9 47.1a ± 1.8
52.9e ± 
0.5
55.4 ± 0.9 58.0 ± 1.4 57.1c ± 0.6 61.1d ± 1.4 56.5c ± 0.9 60.4 ± 1.4
Sertoli cells/mm2 
(n = 4)
6689 ± 
283
6900 ± 
430
6029 ± 
172
7372 ± 440
9428d ± 
383
8498c ± 
354
9099 ± 670 8512c ± 439 9374 ± 576
Germ cells/mm2  
(n = 4)
180 ± 18 133 ± 11 181 ± 25 511c  ± 91 299 ± 42 412c ± 77 275 ± 27 539c ± 116 251 ± 67
BrdU+ germ cells/
mm2 (n = 4)
99.8 ± 5.0
45.3 ± 
19.7
50.5 ± 
15.8
219.1c ± 
31.3
147.6 ± 
17.4
229.4c ± 
43.8
149.6 ± 
17.2
268.3c ± 
51.3
114.5d ± 
33.0
the values presented are means ± SeM, significant difference (p < 0.05) acompared with control value at the age of 5-d-old, bcompared with control 
value at the age of 8-d-old, ccompared with value after similar treatment at the age of 5-d old, dcompared with value after similar treatment without 
imatinib at the age of 8-d-old and eHCA compared with FSH at the same age.© 2012 Landes Bioscience.
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Statistical analysis of the data. The means and SEM val-
ues obtained in independent experiments were calculated. The 
Mann-Whitney Rank Sum test or t-test (pairwise comparison) 
was used for single statistical comparison of independent groups 
of samples. ANOVA followed by the Tukey’s test was employed 
for multiple comparisons. A p value of less than 0.05 was con-
sidered to indicate a statistically significant difference between 
groups.
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patients displaying normal spermatogenesis. The cells, passages 
3–10, were maintained in DMEM supplemented with 10% 
fetal calf serum (FCS; both from PAA GmbH). All participants 
granted written informed consent. The local ethics committee of 
Technical University of Munich approved the study.
To determine viability of cells in culture the CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega GmbH) was used as 
described before in reference 29. Cells were seeded in quadrupli-
cates in 24-well tissue culture plates and incubated for 24 h with/
without imatinib (10, 20, 50 and 100 μM). The kit reagents 
were added directly to the cells and luminescence, as a marker 
of cell viability, was measured with FLUOstar OPTIMA (BMG 
LABTECH GmbH).
For further analysis cells were seeded on 60-mm dishes and 
treated with 5 ng/ml PDGF-BB (human recombinant; Sigma) 
or/and 10 μM imatinib for 4 d. As the PDGF stock was prepared 
in 4 mM HCl containing 0.1% BSA, a 1:1,000 dilution of this 
stock without PDGF was added to the media as a control. Cells 
were trypsinized and numbers determined with an automated 
cell counting device (CASY-system, Casy, Schärfe Systems).28
Cell proliferation was evaluated by counting anaphase, meta-
phase and telophase mitotic figures in HTPCs, stained with 
DAPI (4',6-diamidino-2-phenylindole; 1.5 μg/ml; Vectashield 
mounting medium, Vector Laboratories). Labeling of nuclei was 
done as described previously in reference 30. Mitotic events were 
expressed as percentage of DAPI stained nuclei. At least 200 
nuclei per slide were counted.
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